Stocks
Arena Pharmaceuticals Financial Statements (ARNA) |
||||||||||
| Arena Pharmaceuticalssmart-lab.ru | % | 2017 | 2018 | 2019 | 2020 | 2021 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 14.03.2018 | 28.02.2019 | 27.02.2020 | 23.02.2021 | 23.02.2022 | 23.02.2022 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 21.3 | 18.0 | 806.4 | 0.319 | 0.054 | 0.054 | |||
| Operating Income, bln rub | -92.0 | -144.8 | 482.7 | -426.6 | -612.3 | -625.5 | ||||
| EBITDA, bln rub | ? | -81.0 | -130.2 | 515.9 | -396.4 | -608.4 | -609.5 | |||
| Net profit, bln rub | ? | -91.4 | -29.4 | 397.6 | -404.7 | -620.6 | -617.4 | |||
| OCF, bln rub | ? | -66.6 | -132.2 | 568.7 | -353.1 | -452.0 | -452.0 | |||
| CAPEX, bln rub | ? | 0.113 | 0.692 | 4.82 | 0.820 | 71.0 | 71.0 | |||
| FCF, bln rub | ? | -66.8 | -132.9 | 563.9 | -353.9 | -523.0 | -523.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 101.3 | 162.7 | 323.7 | 426.9 | 554.3 | 554.3 | ||||
| Cost of production, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| R&D, bln rub | 71.0 | 115.0 | 231.5 | 323.7 | 419.5 | 419.5 | ||||
| Interest expenses, bln rub | 6.12 | 5.70 | 4.79 | 4.52 | 4.16 | 3.09 | ||||
| Assets, bln rub | 339.3 | 686.9 | 1 174 | 1 191 | 784.7 | 784.7 | ||||
| Net Assets, bln rub | ? | 207.1 | 606.3 | 1 071 | 1 080 | 673.2 | 673.2 | |||
| Debt, bln rub | 61.7 | 52.7 | 49.4 | 45.6 | 41.2 | 41.2 | ||||
| Cash, bln rub | 247.1 | 445.6 | 739.6 | 1 104 | 550.5 | 550.5 | ||||
| Net debt, bln rub | -185.3 | -392.9 | -690.1 | -1 058 | -509.3 | -509.3 | ||||
| Ordinary share price, rub | 34.0 | 39.0 | 45.4 | 76.8 | 92.9 | 94.0 | ||||
| Number of ordinary shares, mln | 33.0 | 47.0 | 51.7 | 54.8 | 54.8 | 61.4 | ||||
| Market cap, bln rub | 1 121 | 1 832 | 2 348 | 4 208 | 5 090 | 5 767 | ||||
| EV, bln rub | ? | 935 | 1 439 | 1 658 | 3 149 | 4 581 | 5 258 | |||
| Book value, bln rub | 207 | 606 | 1 071 | 1 080 | 673 | 673 | ||||
| EPS, rub | ? | -2.77 | -0.62 | 7.69 | -7.39 | -11.3 | -10.1 | |||
| FCF/share, rub | -2.02 | -2.83 | 10.9 | -6.46 | -9.55 | -8.52 | ||||
| BV/share, rub | 6.28 | 12.9 | 20.7 | 19.7 | 12.3 | 11.0 | ||||
| EBITDA margin, % | ? | -379.7% | -724.6% | 64.0% | -124 249% | -1 126 670% | -1 128 657% | |||
| Net margin, % | ? | -428.4% | -163.6% | 49.3% | -126 876% | -1 149 244% | -1 143 404% | |||
| FCF yield, % | ? | -5.96% | -7.25% | 24.0% | -8.41% | -10.3% | -9.07% | |||
| ROE, % | ? | -44.1% | -4.85% | 37.1% | -37.5% | -92.2% | -91.7% | |||
| ROA, % | ? | -26.9% | -4.28% | 33.9% | -34.0% | -79.1% | -78.7% | |||
| P/E | ? | -12.3 | -62.3 | 5.91 | -10.4 | -8.20 | -9.34 | |||
| P/FCF | -16.8 | -13.8 | 4.16 | -11.9 | -9.73 | -11.0 | ||||
| P/S | ? | 52.5 | 102.0 | 2.91 | 13 190 | 94 260 | 106 798 | |||
| P/BV | ? | 5.41 | 3.02 | 2.19 | 3.89 | 7.56 | 8.57 | |||
| EV/EBITDA | ? | -11.5 | -11.1 | 3.21 | -7.95 | -7.53 | -8.63 | |||
| Debt/EBITDA | 2.29 | 3.02 | -1.34 | 2.67 | 0.84 | 0.84 | ||||
| R&D/CAPEX, % | 62 821% | 16 623% | 4 804% | 39 480% | 591.0% | 591.0% | ||||
| CAPEX/Revenue, % | 0.53% | 3.85% | 0.60% | 257.1% | 131 459% | 131 459% | ||||
| Arena Pharmaceuticals shareholders | ||||||||||
